Naveed had more than 20 years of experience in global drug development and played a significant role in the development and approval of several eye medicines (including Zaditor®/Zaditen®, Rescula®, and Lucentis®). His experience spans startups and large multinational companies, including Novartis. Most recently he was Senior Corporate Officer, Head of Global Research and Development and Chief Scientific Officer at Santen, a global company focused solely on ophthalmology.
We are delighted to welcome Naveed to our team as Chief Scientific Officer. He will be leading research as well as the early clinical development of our investigational RNA therapies.
ProQR has a strong precision medicine platform for inherited retinal diseases with very compelling clinical data, I am delighted to be part of the ProQR team.
A wealth of experience
Naveed is a highly regarded leader and I am excited that he will support our mission to develop medicines for patients that currently have no treatment.
Educational background
After receiving his MD degree from Dow Medical College in Karachi, Pakistan Naveed received his PhD in from the University of South Carolina and completed fellowships at Harvard Medical School and Massachusetts General Hospital. He is a former faculty member at Schepens Eye Research Institute and Harvard Medical School.
Also read the press release announcing his appointment.
